Reuters logo
BRIEF-Synergy Pharmaceuticals says acceptance of SNDA for TRULANCE for treatment of adults with irritable bowel syndrome with constipation
June 7, 2017 / 1:30 PM / 4 months ago

BRIEF-Synergy Pharmaceuticals says acceptance of SNDA for TRULANCE for treatment of adults with irritable bowel syndrome with constipation

June 7 (Reuters) - Synergy Pharmaceuticals Inc:

* Synergy Pharmaceuticals Inc says acceptance of SNDA for Trulance for treatment of adults with irritable bowel syndrome with constipation

* Synergy Pharmaceuticals Inc says prescription drug user fee act (PDUFA) date is January 24, 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below